This trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the ...

Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic ...

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

Glenmark Pharma to launch DCGI-approved Brukinsa in India to advance treatment of haematological malignancies: Our Bureau, Mumbai Monday, June 9, 2025, 14:30 Hrs [IST] Glenmark Ph ...